KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Accumulated Expenses (2016 - 2021)

Biocryst Pharmaceuticals filings provide 9 years of Other Accumulated Expenses readings, the most recent being $3.7 million for Q4 2021.

  • On a quarterly basis, Other Accumulated Expenses fell 24.85% to $3.7 million in Q4 2021 year-over-year; TTM through Dec 2021 was $3.7 million, a 24.85% decrease, with the full-year FY2021 number at $3.7 million, down 24.85% from a year prior.
  • Other Accumulated Expenses hit $3.7 million in Q4 2021 for Biocryst Pharmaceuticals, down from $4.9 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $4.9 million in Q4 2020 to a low of $1.8 million in Q4 2018.
  • Median Other Accumulated Expenses over the past 5 years was $3.5 million (2019), compared with a mean of $3.2 million.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 86.54% in 2019 and later decreased 24.85% in 2021.
  • Biocryst Pharmaceuticals' Other Accumulated Expenses stood at $2.2 million in 2017, then decreased by 17.19% to $1.8 million in 2018, then skyrocketed by 86.54% to $3.5 million in 2019, then surged by 41.81% to $4.9 million in 2020, then decreased by 24.85% to $3.7 million in 2021.
  • The last three reported values for Other Accumulated Expenses were $3.7 million (Q4 2021), $4.9 million (Q4 2020), and $3.5 million (Q4 2019) per Business Quant data.